IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK gained that nod from the FDA in 2017 ... Some other key metrics favored AZ’s medicine. For example, 41% of those who took ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for ...

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Products including untaxed cigarettes, vapes and banned medicine were found during a shop search. GSK Liquor Stop on Dudley ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...

Pharmaceutical companies must prioritize efforts to reach patients in underserved parts of the world with medicines such as insulin for diabetics and, crucially, measure the effectiveness of these ...

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza ... technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this ...